Table 2 Clinical trials HDAC inhibitors used as single agents
From: Histone deacetylase inhibitors: clinical implications for hematological malignancies
Drug | Study | Phase | Disease | NCT | Status |
|---|---|---|---|---|---|
Vorinostat (SAHA) | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | II | PV | NCT00866762 | R |
Vorinostat (SAHA) | Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients | II | FL_indolent NHL MCL | NCT00875056 | ANR |
Vorinostat (SAHA) | MK0683 Phase I Study in CTCL Patients | I | CTCL | NCT00771472 | ANR |
Vorinostat (SAHA) | Phase IIa Vorinostat (MK0683, SAHA) Study in Lower Risk Myelodysplastic Syndromes | II | MDS | NCT00486720 | C |
Vorinostat (SAHA) | A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma | I | Lymphoma | NCT00127140 | ANR |
Vorinostat (SAHA) | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma | III | CTCL | NCT00419367 | ANR |
Vorinostat (SAHA) | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma | II | DLBCL | NCT00097929 | C |
Vorinostat (SAHA) | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma | II | CTCL | NCT00091559 | C |
Vorinostat (SAHA) | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma | I | MM | NCT00109109 | C |
Vorinostat (SAHA) | Vorinostat in Treating Patients With Acute Myeloid Leukemia | II | AML MDS | NCT00305773 | C |
Vorinostat (SAHA) | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | II | PV and ET | NCT00866762 | R |
CHR-2845 | Safety and Tolerability of CHR-2845 to Treat Hematological Diseases or Lymphoid Malignancies (CHR-2845-001) | I | Lymphoid Malignancies | NCT00820508 | R |
Pivanex | A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia | II | CLL, SLL | NCT00083473 | C |
Resminostat (4SC-201) | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin’s Lymphoma (SAPHIRE) | II | HD | NCT01037478 | R |
Panobinostat (LBH 589) | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | II | CTCL, T-ALL | NCT00699296 | C |
Panobinostat (LBH 589) | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | I - II | Lymphoma Leukemia MM | NCT00621244 | A N R |
Panobinostat (LBH 589) | Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma | II - III | PTCL; CTCL | NCT00490776 | C |
Panobinostat (LBH 589) | Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | II | Leukemia | NCT00723203 | R |
Panobinostat (LBH 589) | Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | II | ALL; AML | NCT00723203 | R |
Panobinostat (LBH 589) | Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis | II | MMM | NCT00931762 | R |
Panobinostat (LBH 589) | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin’s Lymphoma | III | HL | NCT01034163 | ANR |
Panobinostat (LBH 589) | Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin’s Lymphom | II | HL | NCT00742027 | ANR |
Panobinostat (LBH 589) | Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | II | ALL | NCT00723203 | R |
Panobinostat (LBH 589) | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | II - III | CTCL | NCT00425555 | ANR |
Panobinostat (LBH 589) | Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis) | II - III | CML | NCT00449761 | C |
Panobinostat (LBH 589) | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | II | CTCL | NCT00699296 | C |
Panobinostat (LBH 589) | LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia | II | WM | NCT00936611 | R |
Panobinostat (LBH 589) | Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase | II - III | CML | NCT00451035 | C |
Panobinostat (LBH 589) | Oral LBH589 in Relapsed or Refractory CLL and MCL | II | CML CLL | NCT01090973 | R |
Panobinostat (LBH 589) | Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma | II - III | CTCL | NCT00490776 | C |
Belinostat (PXD101) | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) | II | PTCL | NCT00865969 | R |
Belinostat (PXD101) | Clinical Trial of PXD101 in Patients With T-Cell Lymphomas | II | CTCL; PTCL; HD | NCT00274651 | A N R |
Belinostat (PXD101) | PXD101 in Treating Patients With Myelodysplastic Syndromes | II | MDS | NCT00357162 | R |
Belinostat (PXD101)) | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) | II | PTCL | NCT01016990 | R |
Givinostat (ITF2357) | Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | II | MM | NCT00792506 | ANR |
Givinostat (ITF2357) | Ph II Study of an HDAC Inhibitor in Very High-Risk Relapsed/Refractory Hodgkin’s Lymphoma Patients | I - II | HD | NCT00496431 | R |
Givinostat (ITF2357) | Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases | II | MPD (JAK2-V617F +) | NCT00606307 | C |
Givinostat (ITF2357) | Phase II Study of Histone-Deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia | II | CLL | NCT00792831 | C |
Givinostat (ITF2357) | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) | II | PV | NCT00928707 | R |
Romidepsin (FK228) | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma | II | Lymphoma | NCT00077194 | C |
Romidepsin (FK228) | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma | II | Lymphoma | NCT00383565 | ANR |
Romidepsin (FK228) | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma | II | CTCL | NCT00106431 | C |
Romidepsin (FK228) | A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma | II | PTCL | NCT00426764 | ANR |
Romidepsin (FK228) | Topical Romidepsin in Treating Patients With Stage I or Stage II Cutaneous T-Cell Non-Hodgkin’s Lymphoma | I | CTCL | NCT00477698 | R |
Romidepsin (FK228) | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | II | MM | NCT00066638 | ANR |
Romidepsin (FK228) | FR901228 in Treating Patients With Hematologic Cancer | I | Leukemia | Â | Â |
Lymphoma | NCT00024180 | C | Â | Â | Â |
Romidepsin (FK228) | FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin’s Lymphoma | II | AML,ALL,MDS,MM,MPN | NCT00042822 | C |
Romidepsin (FK228) | FR901228 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | II | AML | NCT00062075 | ANR |
JNJ-26481585 | A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome. | I | AML, ALL; CML; MDS;B-CLL | NCT00676728 | R |
Mocetinostat (MGCD0103) | A Phase I Study of MGCD0103 Given Three Times Weekly In Patients With Leukemia Or Myelodysplastic Syndrome | I | AML MDS | NCT00324129 | C |
Mocetinostat (MGCD0103) | A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes | I | AML MDS | NCT00324194 | C |
Mocetinostat (MGCD0103) | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | I II | MDS AML | NCT00324220 | C |
Mocetinostat (MGCD0103) | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | II | MDS AML | NCT00374296 | C |
Mocetinostat (MGCD0103) | Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma | II | HL NHL | NCT00359086 | C |
Mocetinostat (MGCD0103) | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | II | MDS AML | NCT00374296 | C |
Mocetinostat (MGCD0103) | Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma | II | NHL HL | NCT00359086 | ANR |
Mocetinostat (MGCD0103) | A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | II | CLL | NCT00431873 | C |
Mocetinostat (MGCD0103) | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin’s Lymphoma | II | HL | NCT00358982 | C |
Entinostat (MS 275) | MS-275 in Treating Patients With Hematologic Cancer | I | Hematological cancers | NCT00015925 | C |
Entinostat (MS 275) | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin’s Lymphoma | II | HL | NCT00866333 | R |